AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32662833
Drug: Yoga or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga or PT (without pain medication)
Trial: 32800383
Drug: Surufatinib 250
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib 250 mg capsules in the fasted state
Trial: 32800383
Drug: Surufatinib 250
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib 250 mg capsules in the fed state
Trial: 32800383
Drug: Surufatinib 250
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib 250 mg capsules (both fasted and fed states)
Trial: 35633431
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment for one year in men aged ≥ 65 years
Trial: 35633431
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone treatment for two years in men aged 50–74 years
Trial: 34117564
Drug: 35% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35% hydrogen peroxide gel (35% HP, commercial gel)
Trial: 34117564
Drug: 35% HP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35% HP and calcium (35% HP + Ca, commercial gel)
Trial: 34013852
Drug: Individual Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Cognitive Behavioural Therapy (ICBT)
Trial: 34013852
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Behavioural Therapy (GCBT)
Trial: 34106473
Drug: Short 3-item
RxNorm normalized name: short ragweed pollen extracts
DrugBank: Ambrosia artemisiifolia pollen (DB10385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short 3-item version of the Montreal Cognitive Assessment (MoCA) administered by telephone
Trial: 32213163
Drug: Neostigmine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (50 mcg/kg plus 10 mcg/kg of atropine)
Trial: 35833308
Drug: Conventional wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional wound treatment
Trial: 35452417
Drug: Wnt/β‐catenin pathway
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wnt/β‐catenin pathway inhibitors
Trial: 35585593
Drug: Shared meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shared meditation intervention (12 weekly sessions of 1.5 hours and a half-day retreat)
Trial: 32644104
Drug: Fluorouracil-based adjuvant
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil-based adjuvant chemotherapy with oxaliplatin
Trial: 34528723
Drug: Pemafibrate 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemafibrate 0.2 mg, orally, twice daily for 72 weeks
Trial: 33413727
Drug: 7.5 g
RxNorm normalized name: glucose 15 GM per 37.5 GM Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 g of salmon fish protein/d
Trial: 35712916
Drug: Guided Self-Help
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided Self-Help (GSH) program, 14 individual sessions over 6 months, 5.3 hours of treatment
Trial: 35712916
Drug: Family-based behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based behavioral treatment (FBT), 20 group-based sessions over 6 months, 20 hours of treatment
Trial: 33401238
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg·kg‐1 of body mass)
Trial: 34387126
Drug: Cardiac neuromodulation
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac neuromodulation therapy (CNT)
Trial: 36038256
Drug: 5 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg/day caffeine citrate
Trial: 36038256
Drug: 10 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg/day caffeine citrate
Trial: 36038256
Drug: 15 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg/day caffeine citrate
Trial: 36038256
Drug: 20 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg/day caffeine citrate
Trial: 34018006
Drug: Intra-articular steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular steroid injection of triamcinolone acetonide (Kenalog)
Trial: 33001143
Drug: Dostarlimab 500
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dostarlimab 500 mg intravenously every 3 weeks for 4 doses, then 1000 mg every 6 weeks until disease progression, treatment discontinuation, or withdrawal
Trial: 37053535
Drug: Trametinib (MEK1/2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trametinib (MEK1/2 inhibitor)
Trial: 35699261
Drug: NRD.E1 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRD.E1 (300 to 1200 mg single dose)
Trial: 35699261
Drug: NRD.E1 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRD.E1 (300 mg once daily for 5 days)
Trial: 35699261
Drug: NRD.E1 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRD.E1 (40 mg under fed and fasted conditions)
Trial: 33627370
Drug: Insomnia prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insomnia prevention program (4 weekly sessions)
Trial: 35672057
Drug: Chemotherapy following
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy following a dose adjusted EPOCH‐R regimen
Trial: 33279779
Drug: Mesalamine induction
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalamine induction therapy
Trial: 32660869
Drug: Trofinetide 70
RxNorm normalized name: Trofinetide
DrugBank: Trofinetide (DB06045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trofinetide 70 mg/kg twice daily
Trial: 32660869
Drug: Trofinetide 35
RxNorm normalized name: Trofinetide
DrugBank: Trofinetide (DB06045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trofinetide 35 mg/kg twice daily
Trial: 34707360
Drug: Hypotensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotensive treatment
Trial: 34923163
Drug: Camrelizumab plus
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab plus chemotherapy (carboplatin and paclitaxel)
Trial: 39102832
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy (carboplatin and paclitaxel)
Trial: 35568194
Drug: BNP <200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP <200 pg/mL (low)
Trial: 35568194
Drug: BNP 200
RxNorm normalized name: BNP
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BNP 200 to <400 pg/mL (moderate)
Trial: 35568194
Drug: BNP ≥400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNP ≥400 pg/mL (high)
Trial: 34684135
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy training (control group), n = 12
Trial: 33979232
Drug: Single-use negative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-use negative pressure wound therapy (sNPWT)
Trial: 34735740
Drug: Psychodynamic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic treatment for BPD
Trial: 32331879
Drug: Flunixin meglumine
RxNorm normalized name: Flunixin Meglumine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunixin meglumine (2.2 mg/kg of BW)
Trial: 32331879
Drug: Isotonic sterile
RxNorm normalized name: Steril-Eyes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic sterile saline solution
Trial: 37071836
Drug: Subcutaneous rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous rituximab
Trial: 32234705
Drug: Intravenous rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous rituximab
Trial: 36114096
Drug: Nab-paclitaxel (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel (100 mg/m² on days 1, 8, and 15 of a 21-day cycle)
Trial: 36114096
Drug: Docetaxel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (60 mg/m² on day 1)
Trial: 32186967
Drug: Self-hypnosis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-hypnosis treatment program
Trial: 34331080
Drug: Topiramate (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (up to 200 mg/day)
Trial: 34740708
Drug: Blonanserin transdermal
RxNorm normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Blonanserin transdermal patches (40-80 mg/day)
Trial: 34740708
Drug: Blonanserin transdermal
RxNorm normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Blonanserin transdermal patches
Trial: 33007780
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate nasal spray (FFNS) 55 µg
Trial: 33007780
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate nasal spray (FFNS) 110 µg
Trial: 33752752
Drug: 5-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-day regimen of post-operative antibiotics
Trial: 33752752
Drug: 1-day regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-day regimen of post-operative antibiotics
Trial: 36197309
Drug: AVT02 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVT02 administered via prefilled syringe (PFS)
Trial: 36197309
Drug: AVT02 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVT02 administered via autoinjector (AI)
Trial: 36197309
Drug: AVT02 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVT02 administered via PFS
Trial: 36197309
Drug: AVT02 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVT02 administered via AI
Trial: 36062569
Drug: Probiotics (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (4 g daily)
Trial: 36062569
Drug: Metformin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1.5 g daily)
Trial: 36062569
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of probiotics and metformin
Trial: 33705475
Drug: Open-label placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label placebo (OLP) plus treatment as usual (TAU)
Trial: 34410203
Drug: Group CBT
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group CBT treatment
Trial: 34073401
Drug: Ivermectin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (single dose according to body weight)
Trial: 34073401
Drug: Standard preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preventive treatment (mainly supplements)
Trial: 33754455
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dosing (0.3 mg/kg/dose)
Trial: 33754455
Drug: Divided dosing
RxNorm normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided dosing (0.15 mg/kg/dose every 8 hours)
Trial: 32195801
Drug: p‐COP‐determined iodine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p‐COP‐determined iodine dose (Group A, n = 65)
Trial: 35103587
Drug: FDC hard
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC hard capsule containing CC/HCTZ/RSV
Trial: 32985902
Drug: Zanubrutinib plus
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib plus rituximab followed by zanubrutinib monotherapy
Trial: 32783367
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist pretreatment (n=172)
Trial: 32783367
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no GnRH agonist pretreatment, n=171)
Trial: 32345077
Drug: 0.25 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 µg alfacalcidol daily for 12 weeks
Trial: 32154928
Drug: Bevacizumab 10
RxNorm normalized name: bevacizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 10 mg/kg every 2 weeks plus trebananib 15 mg/kg every week
Trial: 35038985
Drug: In-Home Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-Home Cognitive Processing Therapy (CPT)
Trial: 35038985
Drug: Telehealth Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth Cognitive Processing Therapy (CPT)
Trial: 35038985
Drug: In-Office Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-Office Cognitive Processing Therapy (CPT)
Trial: 33327240
Drug: Oral Maxing
RxNorm normalized name: Bronkaid Max Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Maxing Shigan Decoction
Trial: 33327240
Drug: Oral Qingfei
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Qingfei Decoction
Trial: 33766084
Drug: Melatonin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin supplementation (250 mg, two tablets once a day for 8 weeks)
Trial: 33151634
Drug: Cognitive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive and behavioral therapy (CBT) plus antidepressants
Trial: 33746024
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (ticagrelor 90 mg twice daily and rivaroxaban 15 mg once daily)
Trial: 33746024
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (aspirin 100 mg and clopidogrel 75 mg once daily combined with dose-adjusted warfarin)
Trial: 33746024
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (ticagrelor plus rivaroxaban)
Trial: 33746024
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (warfarin plus dual antiplatelet therapy)
Trial: 32935904
Drug: Nopal fiber
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nopal fiber 20 g/day
Trial: 32935904
Drug: Nopal fiber
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nopal fiber 30 g/day
Trial: 32935904
Drug: Placebo (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30 g/day dextrose)
Trial: 32682394
Drug: Early Oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early Oral Hydration (EOH) - small amount of drinking water after recovery of swallowing reflex
Trial: 32682394
Drug: Delayed Oral
RxNorm normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed Oral Hydration (DOH) - water administered at 4 hours post-anesthesia
Trial: 35617974
Drug: Lotion
RxNorm normalized name: LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotion
Trial: 32776570
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for ARFID (CBT-AR), 20–30 sessions delivered in family-based or individual format.
Trial: 32776570
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for ARFID (CBT-AR)
Trial: 36438970
Drug: Sham treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatments
Trial: 35485618
Drug: ATVV stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATVV stimulation therapy
Trial: 35388029
Drug: Weekly sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly sessions of psychotherapy for 12 months
Trial: 32991776
Drug: CIN risk
RxNorm normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CIN risk score model based on LVEF < 40%, acute coronary syndrome (ACS), eGFR < 60, and contrast volume > 300 mL.
Trial: 34697566
Drug: Low-dose Betaloc
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Betaloc (≤47.5 mg)
Trial: 34697566
Drug: Medium-dose Betaloc
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-dose Betaloc (47.5-95 mg)
Trial: 34697566
Drug: High-dose Betaloc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Betaloc (142.5-190 mg)
Trial: 33963005
Drug: Automated oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated oxygen titration with the VDL1.1 algorithm
Trial: 35152918
Drug: 2 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg vitamin B12 daily for a year
Trial: 32674594
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments for COVID-19 (specific interventions not detailed)
Trial: 34793864
Drug: Preoperative accelerated
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative accelerated radiotherapy (AF) with 43 fractions, total dose of 68 Gy in 4.5 weeks followed by surgery
Trial: 34793864
Drug: Postoperative conventionally
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative conventionally fractionated radiotherapy (CF), total dose of 60 or 66 Gy in 6-7 weeks
Trial: 36585602
Drug: IL-17 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-17 inhibitors
Trial: 35192788
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) in addition to standard medical care (SMC)
Trial: 34444004
Drug: Immediate Treatment
RxNorm normalized name: Aquaphor Immediate Relief Lip Balm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Treatment Group (IT, n = 10)
Trial: 36000293
Drug: Test linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test linezolid tablet (600 mg)
Trial: 36000293
Drug: Reference linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference linezolid tablet (600 mg)
Trial: 36000293
Drug: Test and
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test and Reference linezolid tablets
Trial: 33735404
Drug: Diagnosis name
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnosis name (AMD) combined with fluorescence fundus angiography and/or anti‐VEGF treatment
Trial: 33735404
Drug: Diagnosis name
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnosis name (AMD) combined with AMD treatment
Trial: 35085443
Drug: Online administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online administration of the Test of Narrative Language-Second Edition (TNL-2)
Trial: 35085443
Drug: In-person administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-person administration of the Test of Narrative Language-Second Edition (TNL-2)
Trial: 32422285
Drug: Topical castor
RxNorm normalized name: Castor Oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical castor oil applied to one eye, twice daily for 4 weeks
Trial: 32422285
Drug: Topical castor
RxNorm normalized name: Castor Oil
DrugBank: Castor oil (DB11113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical castor oil applied to one eye
Trial: 35863559
Drug: Anakinra 100
RxNorm normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra 100 mg, three times per week via the hemodialysis circuit for 24 weeks
Trial: 34521687
Drug: Natalizumab 300
RxNorm normalized name: natalizumab 300 MG in 15 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natalizumab 300 mg IV every 4 weeks for 24 weeks
Trial: 34521687
Drug: Natalizumab 300
RxNorm normalized name: natalizumab 300 MG in 15 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natalizumab 300 mg IV